Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.IJROBP.2006.09.056PMID 17293229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.

  2006cited by this paper
• Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.

  2006cited by this paper
• Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.

  2006cited by this paper
• Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.

  2005cited by this paper
• Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.

  2005cited by this paper
• Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split‐course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies

  2005cited by this paper
• Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

  2005cited by this paper
• State-of-the-art management of locally advanced head and neck cancer

  2005cited by this paper
• Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.

  2004cited by this paper
• The expanding role of systemic therapy in head and neck cancer.

  2004cited by this paper
• Reirradiation of recurrent head and neck cancers with curative intent.

  2004cited by this paper
• Tirapazamine: a hypoxia-activated topoisomerase II poison.

  2002cited by this paper
• RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.

  2001cited by this paper
• Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.

  2001cited by this paper
• Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer.

  2000cited by this paper
• A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

  1998cited by this paper
• Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients.

  1998cited by this paper
• Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.

  1997cited by this paper
• Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

  1997cited by this paper
• Oligometastases.

  1995cited by this paper

• Side effects of boron neutron capture therapy.

  2025cites this paper
• A novel hypoxia‐activated polymeric Tirapazamine derivative for enhanced antitumor therapy

  2023cites this paper
• Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society® (ARS) Appropriate Use Criteria (AUC): Expert Panel on Radiation Oncology - Head and Neck Cancer.

  2022cites this paper
• Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers

  2022cites this paper
• Quinoxaline 1,4-di-N-oxides: a review of the importance of their structure in the development of drugs against infectious diseases and cancer

  2021cites this paper
• Prevention and early management of carotid blowout syndrome for patients receiving head and neck salvage boron neutron capture therapy (BNCT)

  2021cites this paper
• Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy

  2021cites this paper
• Title Boron neutron capture therapy outcomes for advanced orrecurrent head and neck cancer

  2019cites this paper
• Endovascular Treatment for Carotid Blowout Syndrome after Radiation: A Case Report

  2017cites this paper
• A two‐year dietary carcinogenicity study of cyadox in Sprague‐Dawley rats

  2017cites this paper
• Photodynamic Therapy with Liposomal Zinc Phthalocyanine and Tirapazamine Increases Tumor Cell Death via DNA Damage.

  2017cites this paper
• Recurrent/Metastatic Head and Neck Cancer: When and How to Irradiate

  2017cites this paper
• Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.

  2017cites this paper
• Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions

  2016cites this paper
• Carotid blowout syndrome in patients treated by larynx cancer

  2016cites this paper
• Photodynamic therapy with liposomal zinc phthalocyanine and tirapazamine increases tumor cell death via DNA damage

  2016cites this paper
• Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

  2016cites this paper
• Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate

  2015cites this paper
• Local Tumor Control and Normal Tissue Toxicity of Pulsed Low-Dose Rate Radiotherapy for Recurrent Lung Cancer

  2015cites this paper
• Role of reradiation in head and neck cancer from limits to option

  2015cites this paper
• Carotid blowout in patients with head and neck cancer: Associated factors and treatment outcomes

  2015cites this paper
• Deoxidation rates play a critical role in DNA damage mediated by important synthetic drugs, quinoxaline 1,4-dioxides.

  2015cites this paper
• Inferior glucose metabolism and chemosensitivity of post-radiotherapy local recurrence in comparison with distant metastases as assessed by sequential 18F-FDG PET/CT imaging

  2014cites this paper
• Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

  2014cites this paper
• Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer

  2013cites this paper
• Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.

  2013cites this paper
• Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation

  2012cites this paper
• Retreatment of recurrent head and neck cancer in a previously irradiated field.

  2012cites this paper
• Reirradiation for recurrent head and neck carcinoma.

  2012cites this paper
• Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.

  2012cites this paper
• Hypoxia in Head and Neck Squamous Cell Carcinoma

  2012cites this paper
• Risk of carotid blowout after reirradiation of the head and neck: a systematic review.

  2012cites this paper
• Reirradiation in head and neck cancers

  2011cites this paper
• Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation

  2011cites this paper
• Enhanced Antitumor Effect of Tirapazamine Delivered Intraperitoneally to VX2 Liver Tumor-Bearing Rabbits Subjected to Transarterial Hepatic Embolization

  2011cites this paper
• Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer.

  2010cites this paper
• Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.

  2010cites this paper
• [Molecular imaging of tumor hypoxia].

  2009cites this paper
• Imagerie moléculaire de l’hypoxie tumorale

  2009cites this paper
• Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx.

  2009cites this paper
• Cancer of the head and neck is the sixth most common cancer worldwide.

  2009cites this paper
• Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.

  2008cites this paper
• Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer.

  2008cites this paper
• Palliative radiation therapy for head and neck cancer: Toward an optimal fractionation scheme

  2008cites this paper